Cargando…
An open-label, one-year, noncomparative study to evaluate the safety and tolerability of intravitreal pegaptanib sodium in patients with diabetic macular edema
BACKGROUND: The purpose of this study was to evaluate the safety and tolerability of pegaptanib in patients with diabetic macular edema. METHODS: An open-label, multicenter, noncomparative, one-year study of approximately 500 patients was planned. Recruitment was terminated after enrollment of 46 pa...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4149402/ https://www.ncbi.nlm.nih.gov/pubmed/25187694 http://dx.doi.org/10.2147/OPTH.S68498 |
_version_ | 1782332749409943552 |
---|---|
author | Sivaprasad, Sobha Browning, Richard C Starita, Carla |
author_facet | Sivaprasad, Sobha Browning, Richard C Starita, Carla |
author_sort | Sivaprasad, Sobha |
collection | PubMed |
description | BACKGROUND: The purpose of this study was to evaluate the safety and tolerability of pegaptanib in patients with diabetic macular edema. METHODS: An open-label, multicenter, noncomparative, one-year study of approximately 500 patients was planned. Recruitment was terminated after enrollment of 46 patients. Enrolled patients were fully informed and reconsented; 12 patients elected to complete the study. Patients received intravitreal injections of pegaptanib 0.3 mg once every 6 weeks or less frequently, as determined by the investigator. Clinical benefit was evaluated after the patient received two or more injections. Ocular and nonocular adverse events were closely monitored throughout the study. RESULTS: Compared with baseline, mean best-corrected visual acuity increased by week 6. Ten patients reported ocular-related adverse events, none of which were severe, and eight patients reported nonocular adverse events, two of which were severe but unrelated to study treatment. Three serious adverse events, unrelated to study treatment, were reported. CONCLUSION: In this limited set of patients with diabetic macular edema, pegaptanib appeared to be well tolerated with evidence of efficacy. |
format | Online Article Text |
id | pubmed-4149402 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-41494022014-09-03 An open-label, one-year, noncomparative study to evaluate the safety and tolerability of intravitreal pegaptanib sodium in patients with diabetic macular edema Sivaprasad, Sobha Browning, Richard C Starita, Carla Clin Ophthalmol Original Research BACKGROUND: The purpose of this study was to evaluate the safety and tolerability of pegaptanib in patients with diabetic macular edema. METHODS: An open-label, multicenter, noncomparative, one-year study of approximately 500 patients was planned. Recruitment was terminated after enrollment of 46 patients. Enrolled patients were fully informed and reconsented; 12 patients elected to complete the study. Patients received intravitreal injections of pegaptanib 0.3 mg once every 6 weeks or less frequently, as determined by the investigator. Clinical benefit was evaluated after the patient received two or more injections. Ocular and nonocular adverse events were closely monitored throughout the study. RESULTS: Compared with baseline, mean best-corrected visual acuity increased by week 6. Ten patients reported ocular-related adverse events, none of which were severe, and eight patients reported nonocular adverse events, two of which were severe but unrelated to study treatment. Three serious adverse events, unrelated to study treatment, were reported. CONCLUSION: In this limited set of patients with diabetic macular edema, pegaptanib appeared to be well tolerated with evidence of efficacy. Dove Medical Press 2014-08-21 /pmc/articles/PMC4149402/ /pubmed/25187694 http://dx.doi.org/10.2147/OPTH.S68498 Text en © 2014 Sivaprasad et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Sivaprasad, Sobha Browning, Richard C Starita, Carla An open-label, one-year, noncomparative study to evaluate the safety and tolerability of intravitreal pegaptanib sodium in patients with diabetic macular edema |
title | An open-label, one-year, noncomparative study to evaluate the safety and tolerability of intravitreal pegaptanib sodium in patients with diabetic macular edema |
title_full | An open-label, one-year, noncomparative study to evaluate the safety and tolerability of intravitreal pegaptanib sodium in patients with diabetic macular edema |
title_fullStr | An open-label, one-year, noncomparative study to evaluate the safety and tolerability of intravitreal pegaptanib sodium in patients with diabetic macular edema |
title_full_unstemmed | An open-label, one-year, noncomparative study to evaluate the safety and tolerability of intravitreal pegaptanib sodium in patients with diabetic macular edema |
title_short | An open-label, one-year, noncomparative study to evaluate the safety and tolerability of intravitreal pegaptanib sodium in patients with diabetic macular edema |
title_sort | open-label, one-year, noncomparative study to evaluate the safety and tolerability of intravitreal pegaptanib sodium in patients with diabetic macular edema |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4149402/ https://www.ncbi.nlm.nih.gov/pubmed/25187694 http://dx.doi.org/10.2147/OPTH.S68498 |
work_keys_str_mv | AT sivaprasadsobha anopenlabeloneyearnoncomparativestudytoevaluatethesafetyandtolerabilityofintravitrealpegaptanibsodiuminpatientswithdiabeticmacularedema AT browningrichardc anopenlabeloneyearnoncomparativestudytoevaluatethesafetyandtolerabilityofintravitrealpegaptanibsodiuminpatientswithdiabeticmacularedema AT staritacarla anopenlabeloneyearnoncomparativestudytoevaluatethesafetyandtolerabilityofintravitrealpegaptanibsodiuminpatientswithdiabeticmacularedema AT sivaprasadsobha openlabeloneyearnoncomparativestudytoevaluatethesafetyandtolerabilityofintravitrealpegaptanibsodiuminpatientswithdiabeticmacularedema AT browningrichardc openlabeloneyearnoncomparativestudytoevaluatethesafetyandtolerabilityofintravitrealpegaptanibsodiuminpatientswithdiabeticmacularedema AT staritacarla openlabeloneyearnoncomparativestudytoevaluatethesafetyandtolerabilityofintravitrealpegaptanibsodiuminpatientswithdiabeticmacularedema |